mRNA patent trial against BioNTech suspended by German court
Duesseldorf: A German court on Thursday suspended a patent trial against BioNTech over the use of mRNA technology in the COVID-19 vaccine developed by the German company together with its U.S. partner Pfizer.
The Duesseldorf regional court said it needed further clarification and suspended the case, brought by BioNTech competitor CureVac, pending decisions by the German and the European patent offices on a legal challenge filed by BioNTech.
A separate patent infringement case brought by CureVac was previously suspended by the Duesseldorf court because a higher court first needs to review that patent's validity. A decision is expected in December.
Read also: CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
Next Story
